SEEL (Seelos Therapeutics Inc.) Bathi resik saben siji saham sajrone rolas wulan pungkasan

Seelos Therapeutics, Inc (SEEL) - logo korporat

The absence of cash flows and failed tests render the outlook negative, which is confirmed by the Seelos Therapeutics (SEEL) net income per share YoY ttm growth rate chart. The 43.60 mark reflects fresh data amid a liquidity shortage. Risks are exacerbated by capital burn and potential failures in depression therapy, while geopolitics hinder international research, generating losses when tests are halted.

Bathi resik saben saham (EPS TTM) seelostherapeutics.com (SEEL): kanggo periode 11.02.2024 - 20.02.2024

SEEL (seelostherapeutics.com): rincian analitis lan laporan miturut indikator

Pambiji fundamental perusahaan:SEEL, Seelos Therapeutics, Inc.
Barang utama Seelos Therapeutics

To assess the scale of Seelos Therapeutics (SEEL), use the trailing twelve-month (TTM) year-over-year EPS chart. This indicator reflects the dynamics of net income per share relative to the same period last year. The calculation measures business capitalization efficiency and real income growth rates. For this developer of nasal CNS therapies, this metric signals a transition from R&D expenditures to monetization. Steady growth in this metric confirms the company's investment attractiveness.